HUMA HUMACYTE INC revenue, earnings and financials
For the quarter ended June 30, 2026, HUMACYTE INC reported revenue of $406K (up 34.9% from a year earlier), net income of −$36.8M and diluted EPS of −$0.16; over the last four quarters revenue was $2.12M and net income −$96.7M; for the fiscal year ended December 2025 revenue was $2.04M.
HUMA annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $2.04M, gross profit n/a, operating income −$108M, net income −$40.8M (margin -2003.6%), EPS −$0.26
- Fiscal year ended Dec 2024: revenue $0, gross profit n/a, operating income −$114M, net income −$149M (margin n/a), EPS −$1.26
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$100M, net income −$111M (margin n/a), EPS −$1.07
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$84.6M, net income −$12.0M (margin n/a), EPS −$0.12
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$81.2M, net income −$26.5M (margin n/a), EPS −$0.66
HUMA quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $406K (up 34.9% year over year), net income −$36.8M, EPS −$0.16
- Quarter ended Mar 31, 2026: revenue $495K (down 4.3% year over year), net income −$17.6M, EPS −$0.09
- Quarter ended Dec 31, 2025 (from the annual report): revenue $467K, net income −$24.8M, EPS −$0.19
- Quarter ended Sep 30, 2025: revenue $753K, net income −$17.5M, EPS −$0.11
- Quarter ended Jun 30, 2025: revenue $301K, net income −$37.7M, EPS −$0.24
- Quarter ended Mar 31, 2025: revenue $517K, net income $39.1M, EPS $0.28
- Quarter ended Dec 31, 2024 (from the annual report): revenue $0, net income −$20.9M, EPS −$0.16
- Quarter ended Sep 30, 2024: revenue $0, net income −$39.2M, EPS −$0.33
- Quarter ended Jun 30, 2024: revenue $0, net income −$56.7M, EPS −$0.48
- Quarter ended Mar 31, 2024: revenue $0, net income −$31.9M, EPS −$0.29
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$25.1M, EPS −$0.24
- Quarter ended Sep 30, 2023: revenue n/a, net income −$26.0M, EPS −$0.25
- Quarter ended Jun 30, 2023: revenue n/a, net income −$22.7M, EPS −$0.22
- Quarter ended Mar 31, 2023: revenue n/a, net income −$37.0M, EPS −$0.36
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$3.72M, EPS −$0.03
- Quarter ended Sep 30, 2022: revenue n/a, net income −$25.3M, EPS −$0.25
- Quarter ended Jun 30, 2022: revenue n/a, net income $36.9M, EPS $0.35
- Quarter ended Mar 31, 2022: revenue n/a, net income −$19.8M, EPS −$0.19
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income $42.6M, EPS $6.41
- Quarter ended Sep 30, 2021: revenue $241K, net income −$31.6M, EPS −$0.72
HUMA cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$105M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$98.1M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$73.3M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$71.1M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$81.2M, share buybacks n/a
HUMA balance sheet
- Jun 30, 2026: cash $79.9M, total assets $138M, total liabilities $107M, shareholders' equity $31.3M
- Mar 31, 2026: cash $48.5M, total assets $111M, total liabilities $98.9M, shareholders' equity $11.6M
- Dec 31, 2025: cash $50.5M, total assets $116M, total liabilities $113M, shareholders' equity $3.11M
- Sep 30, 2025: cash $19.5M, total assets $91.5M, total liabilities $96.3M, shareholders' equity −$4.75M
- Jun 30, 2025: cash $38.0M, total assets $139M, total liabilities $135M, shareholders' equity $4.05M
- Mar 31, 2025: cash $62.8M, total assets $163M, total liabilities $127M, shareholders' equity $36.0M
- Dec 31, 2024: cash $44.9M, total assets $138M, total liabilities $191M, shareholders' equity −$52.7M
- Sep 30, 2024: cash $20.6M, total assets $115M, total liabilities $178M, shareholders' equity −$63.7M
What is HUMA's revenue?
HUMACYTE INC reported $2.12M of revenue over its last four quarters, through June 30, 2026.
Is HUMA profitable?
No. HUMACYTE INC lost $96.7M over the last four quarters.
What is HUMA's EPS?
Diluted earnings per share over the last four quarters were −$0.55; −$0.16 in the latest quarter.